leisure time -WSS

leisure time

author：entertainment 2025-09-27 16:16:58 - browse：6

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

WSS

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Allen Institute goes after foundational questions, CEO Costa says

Male doctors called my cancer incurable. A female doctor showed it wasn't

EpiPen alternative approval delay highlights citizen petition issue

entertainment

leisure time

focus

Medicare proposal to cover medical devices draws a mixed reaction

How AI helped researchers track recovery from depression

BioMarin wins approval for gene therapy to treat hemophilia A

Arena BioWorks launches in Cambridge to speed drug discovery

Hepatitis C has a cure — but many Americans still lack access to it

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Alkermes shareholders re

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Anesthesiologist group: stop taking Ozempic before surgery

EpiPen alternative approval delay highlights citizen petition issue

knowledge

STAT Virtual Event: Putting AI to the Test

Changes to biosimilar regulatory framework must prioritize patients

Stories you might have missed in 2023: health, science, medicine

Allen Institute goes after foundational questions, CEO Costa says

How Vertex's cystic fibrosis drug is changing patients' lives

Male doctors called my cancer incurable. A female doctor showed it wasn't

leisure time

hotspot

Wikipedia

focus